tiprankstipranks
Claritas Pharmaceuticals (CLAZF)
OTHER OTC:CLAZF
Holding CLAZF?
Track your performance easily

Claritas Pharmaceuticals (CLAZF) Income Statement

25 Followers

Claritas Pharmaceuticals Income Statement

Last quarter (Q3 2021), Claritas Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Claritas Pharmaceuticals's net income was $―. See Claritas Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 20Dec 19Dec 18Dec 17Dec 16
Total Revenue
-$ -1.22M$ -2.22M---
Cost of Revenue
------
Gross Profit
-$ -1.22M$ -2.22M---
Operating Expense
$ 1.22M$ -1.40M$ -4.35M$ 11.10M$ 4.92M$ 5.07M
Operating Income
------
Net Non Operating Interest Income Expense
$ -40.00K$ 2.60M$ 42.00K$ 13.92M$ -17.36M-
Other Income Expense
$ 2.60M$ 3.46M$ 16.43M$ -4.02M--
Pretax Income
$ -3.86M$ -674.00K$ -14.25M$ 6.84M$ -22.28M$ -5.07M
Tax Provision
$ -476.00K$ -4.88M$ -4.62M$ -99.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
------
Basic EPS
-$ 0.01$ -0.05$ 0.04$ 0.26$ -0.39
Diluted EPS
---$ -0.01$ -0.26-
Basic Average Shares
$ 1.22T$ 533.82M$ 448.81M$ 195.51M$ 124.14M-
Diluted Average Shares
---$ 218.34M$ 124.14M-
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
------
Net Income From Continuing And Discontinued Operation
$ -3.38M$ 4.21M$ -9.63M$ 6.93M$ -22.28M$ -5.07M
Normalized Income
$ -1.51M$ 10.07M$ 14.89M$ 9.23M$ -16.38M$ -3.73M
Interest Expense
------
EBIT
$ -3.07M$ -403.00K$ -13.55M$ 7.19M$ -4.91M$ -5.07M
EBITDA
$ -3.07M$ -403.00K$ -13.55M$ 7.19M$ -4.91M$ -5.05M
Currency in USD

Claritas Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis